Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Study of FT-7051 in Men With Metastatic Castration-Resistant Prostate Cancer

X
Trial Profile

A Phase 1 Study of FT-7051 in Men With Metastatic Castration-Resistant Prostate Cancer

Status: Discontinued
Phase of Trial: Phase I

Latest Information Update: 17 Jul 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pocenbrodib (Primary)
  • Indications Adenocarcinoma; Prostate cancer
  • Focus Adverse reactions; First in man
  • Acronyms The Courage study
  • Sponsors FORMA Therapeutics; Novo Nordisk
  • Most Recent Events

    • 02 Mar 2023 Status changed from recruiting to discontinued.
    • 05 Aug 2022 According to a FORMA Therapeutics media release, the company is planning to evaluate an alternative dosing schedule in a less heavily pretreated population and is currently processing the protocol amendment and the company plans to provide updated results in the first half of 2023.
    • 26 May 2022 According to a FORMA Therapeutics media release, as of May 12, 2022, 25 patients have been enrolled in this study. Updated data rom this study is expected in the first half of 2023.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top